Randomized Trialhigh evidence
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial.
Nature medicine·September 9, 2026·PMID 42717033
Why it mattersMyeloperoxidase is implicated in microvascular dysfunction and fibrosis in HFpEF/HFmrEF, but this well-powered trial shows that inhibiting MPO with mitiperstat does not translate into clinical benefit, helping cardiologists avoid ineffective therapy and redirect focus to other mechanisms.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled